 |
|
 |
|
|
|
|
TESTIMONIALS
Brandon B.
I went to sleep at 2am. Up @ 8am. Not only no hangover, but not even the underlying blah feeling. Thanks!!
Danny Gerber.
Encino, CA
I was very skeptical that there was a real product like this. I've tried lots of those packets at gas stations and quick-stop shops that make some big claims, none of them work whatsoever. Sobrietol is truely amazing! I was in shock the next morning when I did not have any hangover symptoms after a long night of drinking.
Frank Honnington.
Los Angeles, CA
Worked like a charm! I took a cab home at 1:30am after having way too many drinks with my friends on Kareoke night. Being 43 years old, I am well aware of how much wine I could consume before reaching the "possible hangover" stage. I went past that stage, took the Sobrietol, and woke up the next morning feeling fine. I was not expecting this at all, this is really an amazing product!
|
|
 |
|
 |
|
Sobrietol History
Since the introduction of concentrated alcoholic beverages thousands of years ago, man has sought some means by which to accelerate the natural rate of alcohol elimination from the body. In early times it was thought that the gemstone amethyst possessed the ability to sober an intoxicated individual. This belief led to the term ‘amethystic’ agent that is still used today for any drug or preparation capable of accelerating ethanol elimination or otherwise sobering an intoxicated individual.
In the absence of bona fide amethystic agents in 1978, Prof. Robert Chambers began in vitro experiments at Auburn University to explore the possibility of using enzymes for ethanol oxidation.
In 1982 David Whitmire entered the Ph.D. program at Auburn to work for Dr. Chambers on enzymatic ethanol detoxification. Whitmire postulated a number of enzymatic systems potentially capable of rapid ethanol oxidation, rapid acetaldehyde oxidation, and cofactor recycling, capabilities necessary for the feasibility of rapid ethanol lowering. Beginning in 1986, after hundreds of in vitro stability experiments and successful in vitro ethanol lowering evaluations, a first-generation enzyme system was used to treat two dogs in four separate experiments. Results from these experiments, published as abstracts, , were sufficiently successful to serve as the basis for an NIH Grant awarded to Whitmire in 1989. In 1988 Whitmire, et al submitted a paper on in vitro ethanol lowering for publication and Dr. Whitmire completed his dissertation and graduated from Auburn.
Supported by the NIH grant, in 1990 Dr. Whitmire joined the University of Georgia to continue ethanol-lowering research with a second-generation enzyme system designed to overcome difficulties inherent in the first-generation enzyme system. In 1995 The University of Georgia Research Foundation filed for a U.S. patent on the technology; the patent was granted in 1998.
In 2005 New Paradigm Health Systems acquired a license for the patented technology from The University of Georgia Research Foundation and is proceeding with commercial development.
|